Post
(Cilnidipine + tadalafil) by AISA Pharma for Raynauds Disease: Likelihood of Approval
(Cilnidipine + tadalafil) is under clinical development by AISA Pharma and currently in Phase II for Raynauds Disease. According to …
RO-7446603 by Genentech USA for Diabetic Macular Edema: Likelihood of Approval
RO-7446603 is under clinical development by Genentech USA and currently in Phase I for Diabetic Macular Edema. According to GlobalData, …
TQB-3454 by Chia Tai Tianqing Pharmaceutical Group for Solid Tumor: Likelihood of Approval
TQB-3454 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Solid Tumor. According …
Decoy-20 by Indaptus Therapeutics for Colorectal Cancer: Likelihood of Approval
Decoy-20 is under clinical development by Indaptus Therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase …
Sintilimab by Innovent Biologics for Metastatic Melanoma: Likelihood of Approval
Sintilimab is under clinical development by Innovent Biologics and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase …
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
MB-272 by Gilead Sciences for Autoimmune Disorders: Likelihood of Approval
MB-272 is under clinical development by Gilead Sciences and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase …
Landiolol hydrochloride by AOP Health for Supraventricular Tachycardia: Likelihood of Approval
Landiolol hydrochloride is under clinical development by AOP Health and currently in Pre-Registration for Supraventricular Tachycardia. According to GlobalData, Pre-Registration …
Nadofaragene firadenovec by Ferring International Center for Malignant Pleural Mesothelioma: Likelihood of Approval
Nadofaragene firadenovec is under clinical development by Ferring International Center and currently in Phase III for Malignant Pleural Mesothelioma. According …
GRANITE-001 by Gritstone Bio for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
GRANITE-001 is under clinical development by Gritstone Bio and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According …
ATRN-119 by Aprea Therapeutics for Solid Tumor: Likelihood of Approval
ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase …
Sym-021 by Les Laboratoires Servier for Solid Tumor: Likelihood of Approval
Sym-021 is under clinical development by Les Laboratoires Servier and currently in Phase I for Solid Tumor. According to GlobalData, …
Setanaxib by Calliditas Therapeutics for Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Likelihood of Approval
Setanaxib is under clinical development by Calliditas Therapeutics and currently in Phase III for Primary Biliary Cholangitis (Primary Biliary Cirrhosis). …
Fruquintinib by Takeda Pharmaceutical for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to …
Decoy-20 by Indaptus Therapeutics for Hepatocellular Carcinoma: Likelihood of Approval
Decoy-20 is under clinical development by Indaptus Therapeutics and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase …
ZNA-1041 by F. Hoffmann-La Roche for Solid Tumor: Likelihood of Approval
ZNA-1041 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Solid Tumor. According to GlobalData, …